BOONE, N.C., Dec. 14, 2017 /PRNewswire/ — Pneuma Respiratory, w
hich has developed the first fully digital, breath-activated soft mist inhaler, will make two presentations at the BioTech Showcase during the 2018 J.P. Morgan Healthcare Conference.
In the first presentation, Pneuma leaders will showcase their integrated device’s ability to deliver multiple types of medicines, which could include large-molecule drugs used to treat non-small cell lung cancer. Such a development would allow Pneuma to disrupt the biologics market. Biologics have garnered significant attention due to their potential cancer-fighting abilities.
The Biotech Showcase presentation is scheduled for 10:15 a.m., Jan. 8 as part of the Franciscan – C track (ballroom level) at Hilton San Francisco Union Square, 333 O’Farrell St., San Francisco. James Bauler, Pneuma’s vice president of business development, will co-present with Dr. Steven Kesten, a pulmonologist with expertise in drug and device development.
The second presentation will highlight details of the novel technology that allows Pneuma to precisely deliver pulmonary drugs such as those used to treat asthma and COPD in a digital breath activated system. The system incorporates Bluetooth technology to monitor exactly when and how often medication is delivered. That presentation is scheduled for 2 p.m., Jan. 9 as part of the Digital Medicine & Medtech Showcase at BioTech. The presentation is part of the B-Cyril Magnin III track.
In recent months, Pneuma has garnered early attention from industry publications, including Mobi Health News, New Atlas and medGadget, due to its one-of-a-kind delivery system.
“The beauty of the Pneuma inhaler is its ability to deliver multiple types of medications through its use of disposable ampoules, breath actuation and electronic ejection,” Bauler said. “Our initial research has shown success delivering off-patent asthma and COPD medications, but we see tremendous potential to lead the successful delivery of large-molecule drugs through the lungs.”
“The enhanced device capability of knowing how often pulmonary drugs are actually delivered has the potential to improve compliance and health outcomes in patients suffering from asthma and COPD,” Kesten said.
As Bauler and Kesten will discuss at the conference, a novel part of Pneuma Respiratory’s digital soft mist device is its ability to deliver different sized droplets of medicine via its droplet ejector technology. This is the technology critical to potentially targeting different areas of the lungs in order to deliver biologics.
Pneuma’s technology allows medication droplets to ride into the lungs on the patient’s breath, without propellants. As a patient inhales, the ejector senses the breath and activates automatically. Early clinical studies have shown that the platform and this technology can effectively deliver a number of different types of medicines to the lungs.
Paired with a mobile app, the device is capable of delivering real-time dose verification data. Dose verification is important for health systems, doctors and patients who are concerned with drug use and compliance.
About Pneuma Respiratory
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of leading researchers, physicians, designers and engineers, Pneuma has created the world’s first fully integrated digital soft mist inhaler. Using exclusive digital droplet ejector technology, Pneuma’s integrated device has the potential to ultimately deliver a spectrum of novel therapies, including biologics, through the lungs. For more information visit www.pneumarespiratory.com.